Tavneos (avacopan) is a first-in-class, orally administered small-molecule inhibitor of the complement 5a receptor (C5aR). It is approved for use in adults with severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). By blocking C5a-mediated neutrophil activation and migration, Tavneos helps to reduce vascular inflammation and organ damage associated with the disease. It is used in combination with standard therapy, including either rituximab or cyclophosphamide, as a steroid-sparing treatment option.

Common side effects may include nausea, headache, liver enzyme elevations, and infection risk. Patients should be monitored for hepatic toxicity and serious infections during treatment.